You are about to leave an AbbVie Canada site, a Web site maintained by AbbVie Corporation.

This link is provided for your convenience only. AbbVie Corporation takes no responsibility for the content of any Web site maintained by any third party and makes no representation as to the accuracy or completeness of any information contained on this or any subsequent link.

Do you wish to leave this site?

Yes No

You are here

Progress @ Work

The Impact of Adalimumab on Work-Related Productivity in Patients With Rheumatoid Arthritis.

    Status Recruiting
    Related Conditions
    Rheumatoid Arthritis

Enrollment Details

Phases: 

  • I
  • II
  • III
  • IV
Study Type:  Observational

This is a type IV phase trial.

Protocol ID
P14-455

Brief summary

Top

The purpose of this study is to describe the impact of treatment with adalimumab on work related productivity and economic burden in patients with Rheumatoid Arthritis (RA) treated in Canada.

Participant Attributes :
  • Male and Female
  • Ages 18 Years to 99 Years

Canada: 30

0
Brampton, ON
1
Mississauga, ON
2
Burlington, ON
3
Mississauga, ON
4
Rimouski, QC
5
Quebec, QC
6
Barrie, ON
7
Ottawa, ON
8
Toronto, ON
9
St. John's, NL
10
Vancouver, BC
11
Sydney, NS
12
Mississauga, ON
13
Winnipeg, MB
14
Mississauga, ON
15
Hamilton, ON
16
Saskatoon, SK
17
Cranbrook, BC
18
Peterborough, ON
19
St. John's, NL
20
Montreal, QC
21
Montreal, QC
22
Owen Sound, ON
23
Nanaimo, BC
24
Etobicoke, ON
25
Montréal, QC
26
Montreal, QC
27
Dundas, ON
28
Ottawa, ON
29
Hamilton, ON
Would you like to know more about this trial?

Study Design

  • The general design that describes the strategy for identifying and following up with participants during observational studies.
    ?

    Observational Model

    Cohort

  • The relationship between the observation period and the time of patient enrollment. Time perspective can be prospective: looking forward using periodic observations usually collected following patient enrollment, or retrospective: looking back using observations usually collected prior to patient selection and enrollment.
    ?

    Time Perspective

    Prospective

    • Subjects with moderate to severe RA for whom the physician has decided to initiate treatment with adalimumab
    • Adult male or female ≥ 18 years old that has been newly prescribed adalimumab therapy according to the local product label and are with PROGRESS
    • Subjects should be evaluated for tuberculosis (TB) exposure/risk factors for active and latent TB
    • Subject is able to give written patient authorization and is willing to comply with the requirements of this study protocol

     

    • Subject cannot or will not sign a patient authorization
    • Subject with a known hypersensitivity to Adalimumab, or any of its components
    • Presence of any condition that, in the opinion of the treating physician, prohibits the subject from participating in the study or obscures the assessment of the treatment of RA
    • Subjects currently participating in an investigational clinical trial
    • Subjects treated with >1 prior biologic disease-modifying antirheumatic drugs (DMARDs) for RA. Any prior treatment with adalimumab is prohibited
    • Subjects previously treated with targeted synthetic disease modifying agent.

     

More on this trial

Clinical Trials.gov